Allakos Inc

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirentelimab's Phase 2a data is promising, particularly for omalizumab-refractory patients, but late-phase results are keys to the drug's validation. Investment Recommendation: Speculative "Buy" advised for bold investors. Initiate starter positions, closely monitor upcoming Phase 2b data and cash burn rate.

Scratching The Surface: Allakos' Novel Take On Urticaria

SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors.

Allakos Appoints Neil Graham to its Board of Directors

BioLife Solutions

Cano Health

Kezar Life Sciences Inc

Alaunos Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors.

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation–

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced an oral presentation at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023.   EAACI is being held June 9-11, 2023 in Hamburg, Germany.

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

Annexon, Inc

eHealth

Fluence Energy

Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge

An analyst bumped his recommendation higher. This closely followed an encouraging quarterly earnings report/business update from the biotech.

Why Allakos Stock Skyrocketed Nearly 9% Higher Today

SAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2023.

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

Allakos is barreling toward two mid-stage data readouts that could alter its long-term outlook. An analyst thinks these twin catalysts could cause the biotech's shares to more than quadruple in value.

Why Allakos Stock Was Heating Up Today

SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company's most advanced antibodies are lirentelimab (AK002) and AK006.

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade

– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent cellular phagocytosis (ADCP) activity –– Allakos plans to initiate the first-in-human study of AK006 during 1H 2023 –

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don't eat me” signal CD24 –– Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-associated myeloid cells and reduced tumor burden in pre-clinical studies –

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer's 37th Annual Meeting

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022.

Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

Results from the phase 2b study, using lirentelimab for the treatment of patients with chronic spontaneous urticaria, are expected in the 2nd half of 2023. Xolair naive CSU cohort of 13 patients started with an average UAS7 score of 18.5 points at baseline and at week 22 dropped down to 4.6 points.

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Alkermes

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Alkermes, Allakos See Activist Action

iBio

Teladoc

The Fed's key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive.

3 Healthcare Stocks to Sell Before They Die

On Monday, biotechnology firm Allakos (NASDAQ: ALLK ) announced a public offering that raised gross proceeds of approximately $150 million, sending ALLK stock soaring 25% in the morning session before paring back modestly heading into the early afternoon hours. Specifically, the company — which focuses on developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases — announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of $5.02 per share.

Why Is Allakos (ALLK) Stock Soaring 25% Today?

Top-line Phase 2b results expected in the second half of 2023 Top-line Phase 2b results expected in the second half of 2023

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint –

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

Investors appear to be getting into position ahead of a major upcoming catalyst.

Why Allakos Stock Is on Fire Today

SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2022.

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors.

News for Allakos Inc Stock (ALLK)